Potential effects of leukotriene receptor antagonist montelukast in treatment of neuroinflammation in parkinson’s disease

Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder where misfolded alpha-synucleinenriched aggregates called Lewy bodies are central in pathogenesis. No neuroprotective or diseasemodifying treatments are currently available. Parkinson’s disease is considered a multifactorial disease and evidence from multiple patient studies and animal models has shown a significant immune component during the course of the disease, highlighting immunomodulation as a potential treatment strategy. The immune changes occur centrally, involving microglia and astrocytes but also peripherally with changes to the innate and adaptive immune system. Here, we review current understanding of different components of the PD immune response with a particular emphasis on the leukotriene pathway. We will also describe evidence of montelukast, a leukotriene receptor antagonist, as a possible anti-inflammatory treatment for PD.